TVTXTravere Therapeutics, Inc.

Travere Therapeutics (NASDAQ:TVTX) is pursuing growth through expanded use of FILSPARI in rare kidney diseases while advancing a late-stage treatment candidate for classical homocystinuria and building its renal pipeline through the recently in-licensed BTK inhibitor civorebrutinib, Chief Financial

FILSPARI net sales surged 96% year-over-year, driven by strong FSGS launch demand.

Earlier this week, Travere Therapeutics reported Q2 2026 results showing revenue rising to US$169.58 million from US$114.45 million a year earlier, alongside a wider net loss of US$34.8 million versus US$12.76 million. The quarter highlighted record demand for FILSPARI, including strong uptake in IgA nephropathy and an early FSGS launch that outperformed internal expectations despite higher losses and a US$40 million convertible note repurchase charge. Next, we’ll examine how FILSPARI’s...

Travere Therapeutics (TVTX) drew investor attention on 4 August 2026 after reporting second quarter results that combined higher revenue with a wider net loss, driven by performance of its rare kidney disease portfolio. See our latest analysis for Travere Therapeutics. At a share price of $62.45, Travere Therapeutics has a 90 day share price return of 46.6% and a 1 year total shareholder return of 269.31%. This suggests momentum has been building around recent revenue beats and interest in...

Ligand stock landed in a profit-taking zone Thursday on a strong second-quarter report and an earnings guidance hike.

Moby summary of Travere Therapeutics, Inc.'s Q2 2026 earnings call

Travere Therapeutics stock has delivered a very strong 341.0% return over the past five years, and the current valuation checks and recent price surge raise questions about how much optimism is already reflected in the share price. Over the last five years, Travere Therapeutics has returned 341.0%, which puts recent gains under closer scrutiny for signs of over optimism in the current price. Recent excitement around the company’s rare disease pipeline can support higher expectations for...

The Dow Jones hit a new high thanks to Nvidia, but Google, SpaceX and AMD weighed on the Nasdaq. Sandisk, Western Digital fell late.

Travere Therapeutics Inc (TVTX) reports record quarterly revenue of $169.6 million, fueled by a 96% surge in FILSPARI sales and successful FSGS launch momentum.

Travere Therapeutics (NASDAQ:TVTX) reported second-quarter results marked by record FILSPARI demand and revenue, driven by continued growth in IgA nephropathy and an early launch in focal segmental glomerulosclerosis, or FSGS. The company generated $161.4 million in U.S. net product sales during th

While the top- and bottom-line numbers for Travere (TVTX) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Travere (TVTX) delivered earnings and revenue surprises of -164.29% and +10.16%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Use the IBD Stock Checklist to separate the wheat from the chaff in the stock market, specifically in the red-hot biotech sector.

LGND stock has risen more than 56.5% so far in 2026. Ligand doesn't make drugs; it forks over funding in exchange for Big Pharma royalties.